EP1895849A4 - Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes - Google Patents

Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes

Info

Publication number
EP1895849A4
EP1895849A4 EP06773171A EP06773171A EP1895849A4 EP 1895849 A4 EP1895849 A4 EP 1895849A4 EP 06773171 A EP06773171 A EP 06773171A EP 06773171 A EP06773171 A EP 06773171A EP 1895849 A4 EP1895849 A4 EP 1895849A4
Authority
EP
European Patent Office
Prior art keywords
beta
treatment
methods
amyloid protein
ocular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06773171A
Other languages
German (de)
English (en)
Other versions
EP1895849A1 (fr
Inventor
Darrick S H L Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/287,080 external-priority patent/US7728043B2/en
Application filed by Individual filed Critical Individual
Publication of EP1895849A1 publication Critical patent/EP1895849A1/fr
Publication of EP1895849A4 publication Critical patent/EP1895849A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06773171A 2005-06-15 2006-06-14 Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes Withdrawn EP1895849A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69081205P 2005-06-15 2005-06-15
US73979705P 2005-11-23 2005-11-23
US11/287,080 US7728043B2 (en) 1999-10-22 2005-11-23 Methods for treatment of beta-amyloid protein-induced ocular disease
PCT/US2006/023197 WO2006138399A1 (fr) 2005-06-15 2006-06-14 Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes

Publications (2)

Publication Number Publication Date
EP1895849A1 EP1895849A1 (fr) 2008-03-12
EP1895849A4 true EP1895849A4 (fr) 2009-11-11

Family

ID=37570771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06773171A Withdrawn EP1895849A4 (fr) 2005-06-15 2006-06-14 Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes

Country Status (3)

Country Link
EP (1) EP1895849A4 (fr)
CA (1) CA2611490A1 (fr)
WO (1) WO2006138399A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2950804B1 (fr) * 2009-10-01 2011-12-23 Oreal Composition, utilisation et procede de conservation
US9365486B2 (en) * 2014-07-01 2016-06-14 Muhammed Majeed Synthesis of calebin-A and its biologically active analogs
CN110229056B (zh) * 2019-06-21 2022-11-08 天津科技大学 一种新型姜黄素类似物及其制备方法和应用
IL310026A (en) * 2021-07-08 2024-03-01 Neuracle Science Co Ltd Inhibitors and methods of using them
EP4437342A1 (fr) * 2021-11-23 2024-10-02 Neuracle Science Co., Ltd. Molécules mimétiques de la famille lrrc4 et utilisations diagnostiques associées

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (fr) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Compositions pharmaceutiques utiles dans la prevention et le traitement d'une maladie induite par la proteine beta-amyloide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101578A1 (en) * 2001-08-03 2004-05-27 Min-Young Kim Compositon containg ginkgo biloba that inhibit angiogenesis and matrix metalloprotinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (fr) * 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Compositions pharmaceutiques utiles dans la prevention et le traitement d'une maladie induite par la proteine beta-amyloide

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BATE C ET AL: "Ginkgolide B inhibits the neurotoxicity of prions or amyloid-[beta] 1-42", JOURNAL OF NEUROINFLAMMATION 20040511 GB, vol. 1, 11 May 2004 (2004-05-11), XP002542118, ISSN: 1742-2094 *
DENTCHEV T ET AL: "Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas", MOLECULAR VISION, MOLECULAR VISION, SN, ATLANTA, 1 September 2003 (2003-09-01), pages 184 - 190, XP003001744, ISSN: 1090-0535 *
JANCIAUSKIENE S ET AL: "Alzheimer's peptide and serine proteinase inhibitors in glaucoma and exfoliation syndrome", DOCUMENTA OPHTHALMOLOGICA 200305 NL, vol. 106, no. 3, May 2003 (2003-05-01), pages 215 - 223, XP002542123, ISSN: 0012-4486 *
JOHNSON L V ET AL: "The Alzheimer's Abeta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 18, 3 September 2002 (2002-09-03), pages 11830 - 11835, XP003000979, ISSN: 0027-8424 *
KIM D S H L ET AL: "Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from [beta]A(1-42) insult", NEUROSCIENCE LETTERS 20010427 IE, vol. 303, no. 1, 27 April 2001 (2001-04-27), pages 57 - 61, XP002542120, ISSN: 0304-3940 *
KIM D S H L ET AL: "Shogaols from Zingiber officinale protect IMR32 human neuroblastoma and normal human umbilical vein endothelial cells from [beta]amyloid(25-35) insult", PLANTA MEDICA 2002 DE, vol. 68, no. 4, 2002, pages 375 - 376, XP002542122, ISSN: 0032-0943 *
KIM DARRICK S H L ET AL: "Side-chain length is important for shogaols in protecting neuronal cells from beta-amyloid insult.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8 MAR 2004, vol. 14, no. 5, 8 March 2004 (2004-03-08), pages 1287 - 1289, XP002542121, ISSN: 0960-894X *
MCKINNON STUART J: "Glaucoma: ocular Alzheimer's disease?", FRONTIERS IN BIOSCIENCE,, vol. 8, 1 September 2003 (2003-09-01), pages s1140 - s1156, XP009121526, ISSN: 1093-4715 *
ONO K ET AL: "Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro", JOURNAL OF NEUROSCIENCE RESEARCH, WILEY-LISS, US, vol. 75, no. 6, 15 March 2004 (2004-03-15), pages 742 - 750, XP002989615, ISSN: 0360-4012 *
PARK, SO-YOUNG: "Discovery of natural products from turmeric and sage that protect cells against beta-amyloid insult", DISSERTATION, 1 January 2001 (2001-01-01), Avail.: UMI, Order No. DA3008089 From: Diss. Abstr. Int., B 2001, 62(3), 1400, XP009121721 *
See also references of WO2006138399A1 *
YAO Z -X ET AL: "The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from [beta]-amyloid-induced cell death by inhibiting the formation of [beta]-amyloid-derived diffusible neurotoxic ligands", BRAIN RESEARCH 20010119 NL, vol. 889, no. 1-2, 19 January 2001 (2001-01-19), pages 181 - 190, XP002542119, ISSN: 0006-8993 *

Also Published As

Publication number Publication date
CA2611490A1 (fr) 2006-12-28
WO2006138399A1 (fr) 2006-12-28
EP1895849A1 (fr) 2008-03-12

Similar Documents

Publication Publication Date Title
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
HK1216235A1 (zh) 使用產後衍生細胞治療外周血管疾病
HK1113797A1 (en) Quinoline derivative for the treatment of retinal diseases
EP1755584A4 (fr) Traitement de la myopie
EG24420A (en) Treatment of ophthalmic conditions
HK1201046A1 (en) Methods of treating ophthalmic diseases
PT1613296E (pt) Métodos para o tratamento da doença de parkinson
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
EP1861126A4 (fr) Traitement de troubles lies a la degradation de proteines
IL185052A0 (en) Treatment of bone disorders
SI2056863T1 (sl) Zdravljenje očesnih bolezni
IL190779A0 (en) Compositions for treatment of eye diseases
EP1962869A4 (fr) Traitement de maladies respiratoires
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1858499A4 (fr) Methodes de traitement de maladie degenerative retinienne
EP1895849A4 (fr) Procedes pour le traitement de maladies oculaires induites par les proteines beta-amyloidiennes
EP1768656A4 (fr) Traitement de maladies oculaires
ZA200806095B (en) Means and methods for the treatment of tumorous diseases
EP1901770A4 (fr) Methodes permettant de traiter les troubles de la croissance
GB0523964D0 (en) The treatment of ophthalmic diseases
EP1846013A4 (fr) Traitement de dermatoses
GB0426196D0 (en) Methods of treatment
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
GB0523965D0 (en) The treatment of ophthalmic diseases
GB0523962D0 (en) The treatment of ophthalmic diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/343 20060101ALI20090828BHEP

Ipc: A61K 31/352 20060101ALI20090828BHEP

Ipc: A61K 31/60 20060101ALI20090828BHEP

Ipc: A61K 31/05 20060101AFI20090828BHEP

Ipc: A01N 65/00 20090101ALI20090828BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090907

17Q First examination report despatched

Effective date: 20100115

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100730